The information is entered into a computerised database which allows reaction scores to be calculated both for individual patients, and for treatment groups. This system enables comparision of adverse ocular reactions to various new chemotherapeutic regimens.
Onchoceriasis, a parasitic disease caused by the nematode wonn Onchocerca volvulus, is a major cause of preven table blindness in Africa, Central and South America. Chemotherapy of onchocerciasis has been complicated by severe systemicl-3 and ocular4--6 reactions induced by death of microfilariae. Severe symptoms following drug administration may lead to non-compliance with therapy, and ocular inflammation may precipitate or aggravate visual disability. Methods to quantify systemic reactions during therapy have been devised,7-9 and recently an ocular reaction index based only on anterior segment inflammatory signs and ocular microfilarial loads was described. 10 The posterior segment changes were not add ressed although it is reactions in the retina and optic nerve which represent the major risk of therapy. For this reason a new assessment method has been created which provides a more complete index of ocular disease. The method described in this paper includes symptoms, changes in visual function, anterior segment inflammation and disease of the posterior segment. This complements the systemic assessment which is carried out routinely at the Onchocerciasis Chemotherapy Research Centre (OCRC). Uncorrected visual acuity with each eye is measured at six metres using an illiterate 'E' chart, and scored. (Table I) Visual fields are recorded using a standardised Gold mann perimeter with I/4e and 1/2e white targets, The 1/4e isopter is recorded from non-seeing to seeing areas to obtain a peripheral field. A similar field is recorded to 1/2e, If loss to the 1/4e target is detected, a visual field is under taken to the IV/4e, Intersects between the radial and cir cumferential lines on the Goldmann chart outside the seeing field within the central 50° to IV /4e, within the cen tral 40° to I/4e and within the central 200e to the I/2e targes are counted and scored, (Table II) ,
In addition static perimetry with targets presented randomly for at least one second is recorded with 1/2 at eccentricities of 5°, 10°, 15° and 20° on alternate 30° radial lines of the Goldmann chart plus the four quadrants within 5° making a total of 52 presentations, Missed I/2e static presentations are also counted and scored, two missed presentations being allowed for the blind spot. (Table II) Scoring is therefore weighted to the detection of early field loss.
Anterior segment inflammation: Microfilarial death, whether spontaneous or drug induced, may result in a con junctivitis, limbitis and onchocercal punctate keratitis, Anterior uveitis may also complicate the clinical picture, Although these changes do not usually result in blindness, they have been included as they represent host response to the parasite. During examination of the anterior segment, ocular parasites in the anterior chamber and cornea are counted, although these counts are not considered in the scoring of ocular reactions, Signs of inflammation are graded and scored. (Table III ) Aqueous flare is quantified (Filters I and 2 are neutral density filters built into the optical column of the slit lamp, filter 2 being the denser one).
by interposing the neutral density filters in the Haag-Streit optical column and noting when it becomes just visible in a beam of light 0.2 mm wide at an angle of 45°, using six volts for illumination. Aqueous cells are counted in a Table IV . Scoring system for disease of the posterior segment M. HERO ET AL.
column of light 0.5 mm wide by 2 mm high incident at 45°.
Disease of the posterior segment: Colour or red-free photographs and fluorescein angiograms are used for scor ing pigment epithelial and choroidal changes, papillitis and optic atrophy. Scoring of posterior segment changes has been based on well recognised patterns of retinal and optic nerve disease in onchocerciasis. (Table IV) The system takes account of both the intensity and distribution of disease. The initial retinal pigment epithelial changes appear characteristically as irregularity of the pigmentation 10° temporal to the fovea, or occasionally nasal to the optic disc (Fig. 1) . With advancing disease there is gradual extension of pigment epithelial changes around the mac ula, and intensification of atrophy. Increased intensity of atrophy and extension of disease do not necessarily go hand in hand so that each is considered separately (Fig. 2) . The typical end stage appearance of the' Ridley fundus' in which the whole macula is affected and there is reactive hyperpigmentation is awarded a score of 20 under both distribution and atrophy (Fig. 3) .
Early papilitis is detected only by fluorescein angiog raphy, (Fig. 4) but in the later stages disc hyperaemia and swelling become evident ophthalmoscopically. The swell ing is usually segmental initially, but involves the whole disc with advancing disease. The earliest sign of loss of ganglion cell axons is identified as linear defects in the reflex of the inner retina. Segmental then overall disc pal lor and total loss of nerve fibre bundles may occur in advanced optic nerve atrophy. These signs can be recog nised on both colour and red-free photographs. Other changes attributable to onchocerciasis such as vasculitis, cotton wool spots and retinal haemorrhages each receive a score of five. The scores for these lesions are carried over to scores for subsequent visits even if the lesions disappear, as they represent destructive retinal processes.
Photographs are scored by two masked observers, any difference between the two scores being decided after consultation. The practicability of the system for posterior segment changes was tested by two masked observers scoring colour and red-free photographs, and fluorescein angiograms of 120 healthy males aged 18-50 years who were recruited to chemotherapeutic trials. The concord ance was between 85% and 90% for the different attri butes of fundus disease.
Baseline scores and the effect of treatment: Changes occurring during therapy may be registered if there is a change in the category of any lesion. If there is progression of a lesion which is insufficient to change category, one is added to the previous score. Thus, four episodes of deterioration may be recorded without changing category.
Clinical information is entered into a computerised database which has been programmed to award appro priate scores for the clinical findings. Individual scores for each separate feature when added together produce the total score for that patient. This allows changes to be detected for each clinical attribute and for a patient as a whole over time. By recording change, it also enables comparison of ocular reactions between different treat ment groups in a therapeutic trial, and the important reac tion patterns to treatment may be identified by analysing individual components of disease separately.
DISCUSSION
The parameters chosen for this assessment have been selected to represent certain features found in untreated disease which may be aggravated by chemotherapy and adversely affect visual outcome. Symptoms have been included in this system as they represent the patient's con ception of his disease, and a drug causing severe symp toms may prove unacceptable for community use. However, owing to the difficulty in assessing ocular symptoms, the maximum score per patient has been lim ited to five to prevent undue weight being given to this fea ture. It is evident that the scoring system for specific features of disease cannot be considered as equivalents, and that the numerical progression in any aspect is not linear. Nevertheless the system includes those aspects of disease which are important indicators of progression, and some weighting can be given to those features which are most threatening to vision. Above all it allows change to be documented over time, and provides a protocol which can be used to detect reaction to treatment.
Unlike the 'reaction index' by Keyvan-Larijani et a/iD microfilarial counts in the anterior chamber and cornea are not included in scoring disease. Ocular microfilarial counts following therapy are determined by both microfil arial migration and death. Ivermectin has been shown to increase anterior chamber parasite counts without indu cing significant inflammation as part of the therapeutic effect such that it should not be considered an adverse reaction. 12 Incorporation of corneal microfilarial counts would lead to an increased score early in disease, thus giving the erroneous impression of a complication of ther apy. Furthermore, a rise in the score attributable to ocular inflammatory changes could be masked in the total score by a subsequent fall in ocular microfilarial counts. This is analogous to the procedure employed in the quantification of systemic reactions where skin microfilarial counts are not utilised. 7 -9 It is well accepted that chorioretinal changes and optic atrophy account for significant visual morbidity in oncho cerciasis, and aggravation of posterior segment disease represents the major threat from treatment. TypicaJly good acuity is maintained until late in the disease when visual loss may be precipitate. Visual field loss however is an early manifestation of optic nerve involvement making it essential to detect and quantify visual field loss. Therapy with microfilaricidal drugs inducing an inflammatory reaction around microfilariae, such as diethylcarbamazine citrate (DEC-C), may accelerate optic nerve disease lead ing to permanent loss of visual function. 6 Transient pig ment epithelial lesions detectable only on fluorescein angiography have been demonstrated following DEC-C administration. In direct contrast to DEC-C, Ivermectin, also an effective microfilaricide has not yet been shown to induce fresh posterior segment lesions or to accelerate pre-existing disease.
}2 Owing to the unpredictable and potentially damaging effects of fil aricidal drugs on the evolution of disease of the posterior segment any method for quantifying reactions to onchocerciasis therapy must include this feature.
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Our aim in constructing the method described in this paper is to summarise numerically adverse ocular reac tions to filaricide therapy in a way which complements the assessment of systemic reactions but with due regard being given to the cumulative effects of ocular damage. It also permits the comparison of adverse reactions and iden tification of particular reaction patterns to different che motherapeutic regimens.
